Trial · NCT02374567
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567, Phase 3, Terminated, Hannover Medical School
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacovigilance in Gerontopsychiatric Patients. Trials, record NCT02374567. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02374567
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacovigilance in Gerontopsychiatric Patients
- NCT number
- NCT02374567
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 407 participants, actual
- Lead sponsor
- Hannover Medical School
- Conditions
- Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
- Interventions
Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Valproic Acid, Lamotrigine, Topiramate, Gabapentin, Levetiracetam, Pregabalin, Lacosamide, Clonazepam, Biperiden, Levomepromazine, Fluphenazine, Perphenazine, Perazine, Thioridazine, Haloperidol, Melperone, Pipamperone, Bromperidol, Benperidol, Sertindole, Ziprasidone, Flupentixol, Chlorprothixene, Zuclopenthixol, Fluspirilene, Pimozide, Clozapine, Olanzapine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Prothipendyl, Risperidone, Aripiprazole, Paliperidone, Diazepam, Oxazepam, Lorazepam, Bromazepam, Clobazam, Alprazolam, Hydroxyzine, Buspirone, Chloral Hydrate, Flurazepam, Nitrazepam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Zopiclone, Zolpidem, Zaleplon, Melatonin, Clomethiazole, Diphenhydramine, Promethazine, Imipramine, Clomipramine, Opipramol, Trimipramine, Amitriptyline, Nortriptyline, Doxepin, Maprotiline, Amitriptyline oxide, Fluoxetine, Citalopram, Paroxetine, Sertraline, Fluvoxamine, Escitalopram, Tranylcypromine, Moclobemide, Mianserin, Trazodone, Mirtazapine, Bupropion, Venlafaxine, Reboxetine, Duloxetine, Agomelatine, Pyritinol, Piracetam, Donepezil, Rivastigmine, Galantamine, Memantine, Nicergoline, Acamprosate, Lithium
- First posted
- 2015-03-02
- Last updated
- 2018-02-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of frequency and severity of adverse events | Participants will be followed for the duration of hospital stay and the follow-up-visit, an expected average of 6 weeks | |
| Secondary | Assessment of cognitive functioning | At baseline visit and at the final visit (expected average of hospital stay: 4 weeks) | Mini mental state examination, intensive care delirium checklist |
| Secondary | Quality of life | At baseline visit and at the final visit (expected average of hospital stay: 4 weeks) | SF-8 |
| Secondary | Adverse drug reactions | Continuously during hospital stay (expected average of hospital stay: 4 weeks) and at follow-up two weeks after discharge | Dosage record and treatment emergent symptoms scale (DOTES), geriatric adverse event rating scale (GEARS) |
| Secondary | Serum level of substances | 1 day at occurrence of SAR | |
| Secondary | Electrocardiogram | At baseline visit, at occurrence of SAR and at the final visit (expected average of hospital stay: 4 weeks) | |
| Secondary | Medication intake | Patients medication intake 2 weeks before hospitalization, continuously during hospital stay (expected average of hospital stay: 4 weeks) and at follow-up two weeks after discharge | Morisky medication adherence scale (MMAS) and chart review |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02374567
GET https://conductscience.org/api/trials/v1/NCT02374567/registered